1. Anti-PD-1 antibody treatment for melanoma – Authors' reply. Issue 5 (May 2018) Authors: Beaver, Julia A; Keegan, Patricia; Lemery, Steven; Pazdur, Richard; Theoret, Marc R Journal: Lancet oncology Issue: Volume 19:Issue 5(2018) Page Start: e220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Issue 2 (February 2020) Authors: Gao, Jennifer J; Cheng, Joyce; Bloomquist, Erik; Sanchez, Jacquelyn; Wedam, Suparna B; Singh, Harpreet; Amiri-Kordestani, Laleh; Ibrahim, Amna; Sridhara, Rajeshwari; Goldberg, Kirsten B; Theoret, Marc R; Kluetz, Paul G; Blumenthal, Gideon M; Pazdur, Richard; Beaver, Julia A; Prowell, Tatiana M Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: 250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. Issue 3 (4th March 2021) Authors: Madan, Ravi A; Karzai, Fatima; Donahue, Renee N; Al-Harthy, Munjid; Bilusic, Marijo; Rosner, Inger I; Singh, Harpreet; Arlen, Philip M; Theoret, Marc R; Marté, Jennifer L; Cordes, Lisa; Couvillon, Anna; Hankin, Amy; Williams, Moniquea; Owens, Helen; Lochrin, Sarah E; Chau, Cindy H; Steinberg, Set... Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. Issue 1 (26th February 2020) Authors: Mulkey, Flora; Theoret, Marc R; Keegan, Patricia; Pazdur, Richard; Sridhara, Rajeshwari Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial. (8th February 2022) Authors: Pulte, E Dianne; Chen, Haiyan; Price, Lauren S L; Gudi, Ramadevi; Li, Hongshan; Okusanya, Olanrewaju O; Ma, Lian; Rodriguez, Lisa; Vallejo, Jonathon; Norsworthy, Kelly J; de Claro, R Angelo; Theoret, Marc R; Pazdur, Richard Journal: Oncologist Issue: Volume 27:Number 2(2022) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions. (June 2019) Authors: King-Kallimanis, Bellinda L; Howie, Lynn J; Roydhouse, Jessica K; Singh, Harpreet; Theoret, Marc R; Blumenthal, Gideon M; Kluetz, Paul G Journal: Clinical trials Issue: Volume 16:Number 3(2019) Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Issue 2 (February 2018) Authors: Beaver, Julia A; Hazarika, Maitreyee; Mulkey, Flora; Mushti, Sirisha; Chen, Huanyu; He, Kun; Sridhara, Rajeshwari; Goldberg, Kirsten B; Chuk, Meredith K; Chi, Dow-Chung; Chang, Jennie; Barone, Amy; Balasubramaniam, Sanjeeve; Blumenthal, Gideon M; Keegan, Patricia; Pazdur, Richard; Theoret, Marc R Journal: Lancet oncology Issue: Volume 19:Issue 2(2018) Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Issue 9 (September 2021) Authors: Fallah, Jaleh; Zhang, Lijun; Amatya, Anup; Gong, Yutao; King-Kallimanis, Bellinda; Bhatnagar, Vishal; Weinstock, Chana; Suzman, Daniel L; Agrawal, Sundeep; Chang, Elaine; Anscher, Mitchell S; Chi, Dow-Chung; Xu, James X; Brewer, Jamie R; Brave, Michael H; Hadadi, Mehrnoosh; Theoret, Marc R; Kluet... Journal: Lancet oncology Issue: Volume 22:Issue 9(2021) Page Start: 1230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗